Anne Vanlent
CIK 1229243 · Exec VP & CFO · last filed 2026-06-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
IART price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
NEW HAVEN, CT 06510
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TRVI | Director | 20,983 | $14.14 | $296.7K | $50.0K | 10 | 2026-06-04 |
| APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted | Director | — | $0.39 | — | $0 | 9 | 2022-12-01 |
| Vaxart, Inc. (VXRT) Delisted | Director | — | $0.32 | — | $0 | 1 | 2019-06-14 |
| AVIR | Director | — | $4.27 | — | $0 | 2 | 2017-05-22 |
| NOVELION THERAPEUTICS INC. (NVLN) Delisted | Director | — | — | — | $0 | 1 | 2016-12-27 |
| Aegerion Pharmaceuticals, Inc. (AEGR) Delisted | Director | 0 | — | — | $0 | 3 | 2016-11-30 |
| Vaxart, Inc. (BOTA) Delisted | Director | 35,000 | — | — | $76.9K | 4 | 2015-08-13 |
| ONTX | Director | — | $5.04 | — | $0 | 3 | 2015-06-17 |
| Ocera Therapeutics, Inc. (TZYM) Delisted | Director | — | — | — | $0 | 2 | 2012-08-09 |
| IART | Director | 16,956 | $13.44 | $227.9K | -$250.3K | 8 | 2012-05-21 |
| PENWEST PHARMACEUTICALS CO (PPCO) Delisted | Director | 0 | — | — | -$7.0K | 8 | 2010-09-22 |
| BARRIER THERAPEUTICS INC (BTRX) Delisted | Exec VP & CFO | 148,852 | — | — | $0 | 2 | 2008-03-17 |
Recent Filings · Page 5 of 6
59 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2012-05-21 | IART | Grant (A) | +2,500 | $0 | EDGAR |
| 2011-05-19 | IART | Grant (A) | +2,500 | $0 | EDGAR |
| 2011-04-21 | Ocera Therapeutics, Inc. (TZYM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-01-14 | IART | Mixed | +2,230 | -$377 | EDGAR |
| 2010-09-22 | PENWEST PHARMACEUTICALS CO (PPCO) Delisted | U | −50,491 | $0 | EDGAR |
| 2010-05-21 | IART | Grant (A) | — | $0 | EDGAR |
| 2010-01-05 | PENWEST PHARMACEUTICALS CO (PPCO) Delisted | Grant (A) | +6,000 | $0 | EDGAR |
| 2009-05-22 | IART | Grant (A) | — | $0 | EDGAR |
| 2009-01-05 | PENWEST PHARMACEUTICALS CO (PPCO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2008-12-09 | IART | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.